Literature DB >> 23979159

Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis.

Benjamin D Humphreys1, Fengfeng Xu, Venkata Sabbisetti, Ivica Grgic, Said Movahedi Naini, Ningning Wang, Guochun Chen, Sheng Xiao, Dhruti Patel, Joel M Henderson, Takaharu Ichimura, Shan Mou, Savuth Soeung, Andrew P McMahon, Vijay K Kuchroo, Joseph V Bonventre.   

Abstract

Acute kidney injury predisposes patients to the development of both chronic kidney disease and end-stage renal failure, but the molecular details underlying this important clinical association remain obscure. We report that kidney injury molecule-1 (KIM-1), an epithelial phosphatidylserine receptor expressed transiently after acute injury and chronically in fibrotic renal disease, promotes kidney fibrosis. Conditional expression of KIM-1 in renal epithelial cells (Kim1(RECtg)) in the absence of an injury stimulus resulted in focal epithelial vacuolization at birth, but otherwise normal tubule histology and kidney function. By 4 weeks of age, Kim1(RECtg) mice developed spontaneous and progressive interstitial kidney inflammation with fibrosis, leading to renal failure with anemia, proteinuria, hyperphosphatemia, hypertension, cardiac hypertrophy, and death, analogous to progressive kidney disease in humans. Kim1(RECtg) kidneys had elevated expression of proinflammatory monocyte chemotactic protein-1 (MCP-1) at early time points. Heterologous expression of KIM-1 in an immortalized proximal tubule cell line triggered MCP-1 secretion and increased MCP-1-dependent macrophage chemotaxis. In mice expressing a mutant, truncated KIM-1 polypeptide, experimental kidney fibrosis was ameliorated with reduced levels of MCP-1, consistent with a profibrotic role for native KIM-1. Thus, sustained KIM-1 expression promotes kidney fibrosis and provides a link between acute and recurrent injury with progressive chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979159      PMCID: PMC3755983          DOI: 10.1172/JCI45361

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

Review 1.  Linking the population epidemiology of acute renal failure, chronic kidney disease and end-stage renal disease.

Authors:  Chi-yuan Hsu
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-05       Impact factor: 2.894

2.  Epitope-dependent effect of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses.

Authors:  Irene D Sizing; Véronique Bailly; Patricia McCoon; Wenjie Chang; Sambasiva Rao; Lourdes Pablo; Rachel Rennard; Meghan Walsh; Zhifang Li; Mohammad Zafari; Max Dobles; Leticia Tarilonte; Steven Miklasz; Gerard Majeau; Kevin Godbout; Martin L Scott; Paul D Rennert
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

3.  Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.

Authors:  Jazmin Pérez-Rojas; Jorge A Blanco; Cristino Cruz; Joyce Trujillo; Vishal S Vaidya; Norma Uribe; Joseph V Bonventre; Gerardo Gamba; Norma A Bobadilla
Journal:  Am J Physiol Renal Physiol       Date:  2006-07-11

4.  Prevention of kidney ischemia/reperfusion-induced functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction.

Authors:  Kwon Moo Park; Cornelis Kramers; Muriel Vayssier-Taussat; Ang Chen; Joseph V Bonventre
Journal:  J Biol Chem       Date:  2001-11-05       Impact factor: 5.157

5.  Tubular kidney injury molecule-1 (KIM-1) in human renal disease.

Authors:  M M van Timmeren; M C van den Heuvel; V Bailly; S J L Bakker; H van Goor; C A Stegeman
Journal:  J Pathol       Date:  2007-06       Impact factor: 7.996

6.  The commonly used beta-actin-GFP transgenic mouse strain develops a distinct type of glomerulosclerosis.

Authors:  Jian-Kan Guo; Ee-Chun Cheng; Lin Wang; E Scott Swenson; Thomas A Ardito; Michael Kashgarian; Lloyd G Cantley; Diane S Krause
Journal:  Transgenic Res       Date:  2007-06-27       Impact factor: 2.788

7.  Identification of Tim4 as a phosphatidylserine receptor.

Authors:  Masanori Miyanishi; Kazutoshi Tada; Masato Koike; Yasuo Uchiyama; Toshio Kitamura; Shigekazu Nagata
Journal:  Nature       Date:  2007-10-24       Impact factor: 49.962

8.  Tubular kidney injury molecule-1 in protein-overload nephropathy.

Authors:  Mirjan M van Timmeren; Stephan J L Bakker; Vishal S Vaidya; Veronique Bailly; Theo A Schuurs; Jeffrey Damman; Coen A Stegeman; Joseph V Bonventre; Harry van Goor
Journal:  Am J Physiol Renal Physiol       Date:  2006-02-07

9.  Community-based incidence of acute renal failure.

Authors:  C-Y Hsu; C E McCulloch; D Fan; J D Ordoñez; G M Chertow; A S Go
Journal:  Kidney Int       Date:  2007-05-16       Impact factor: 10.612

10.  TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells.

Authors:  Norimoto Kobayashi; Piia Karisola; Victor Peña-Cruz; David M Dorfman; Masahisa Jinushi; Sarah E Umetsu; Manish J Butte; Haruo Nagumo; Irene Chernova; Baogong Zhu; Arlene H Sharpe; Susumu Ito; Glenn Dranoff; Gerardo G Kaplan; Jose M Casasnovas; Dale T Umetsu; Rosemarie H Dekruyff; Gordon J Freeman
Journal:  Immunity       Date:  2007-12       Impact factor: 31.745

View more
  126 in total

Review 1.  Biomarkers in chronic kidney disease, from kidney function to kidney damage.

Authors:  Salvador Lopez-Giacoman; Magdalena Madero
Journal:  World J Nephrol       Date:  2015-02-06

2.  Renal fibrosis: KIM-1 expression links kidney injury with CKD in mice.

Authors:  Rebecca Kirk
Journal:  Nat Rev Nephrol       Date:  2013-09-17       Impact factor: 28.314

3.  Fluorescence microangiography for quantitative assessment of peritubular capillary changes after AKI in mice.

Authors:  Rafael Kramann; Mari Tanaka; Benjamin D Humphreys
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

4.  Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes.

Authors:  Carissa Vinovskis; Lu-Ping Li; Pottumarthi Prasad; Kalie Tommerdahl; Laura Pyle; Robert G Nelson; Meda E Pavkov; Daniel van Raalte; Marian Rewers; Marlon Pragnell; Farid H Mahmud; David Z Cherney; Richard J Johnson; Kristen J Nadeau; Petter Bjornstad
Journal:  Diabetes       Date:  2020-07-31       Impact factor: 9.461

Review 5.  Controversies on the origin of proliferating epithelial cells after kidney injury.

Authors:  Tetsuro Kusaba; Benjamin D Humphreys
Journal:  Pediatr Nephrol       Date:  2013-12-10       Impact factor: 3.714

6.  Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Authors:  Natalia Nowak; Jan Skupien; Adam M Smiles; Masayuki Yamanouchi; Monika A Niewczas; Andrzej T Galecki; Kevin L Duffin; Matthew D Breyer; Nick Pullen; Joseph V Bonventre; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2018-02-02       Impact factor: 10.612

7.  Mapping and functional characterization of murine kidney injury molecule-1 proteolytic cleavage site.

Authors:  Saranga Sriranganathan; Elena Tutunea-Fatan; Alina Abbasi; Lakshman Gunaratnam
Journal:  Mol Cell Biochem       Date:  2020-11-19       Impact factor: 3.396

Review 8.  The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction.

Authors:  Robert L Chevalier
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18

9.  Translational profiles of medullary myofibroblasts during kidney fibrosis.

Authors:  Ivica Grgic; A Michaela Krautzberger; Andreas Hofmeister; Matthew Lalli; Derek P DiRocco; Susanne V Fleig; Jing Liu; Jeremy S Duffield; Andrew P McMahon; Bruce Aronow; Benjamin D Humphreys
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

10.  KIM-1-/TIM-1-mediated phagocytosis links ATG5-/ULK1-dependent clearance of apoptotic cells to antigen presentation.

Authors:  Craig R Brooks; Melissa Y Yeung; Yang S Brooks; Hui Chen; Takaharu Ichimura; Joel M Henderson; Joseph V Bonventre
Journal:  EMBO J       Date:  2015-08-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.